GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Valuation Rank

MDXH (MDxHealth) Valuation Rank


View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MDxHealth Valuation Rank Related Terms

Thank you for viewing the detailed overview of MDxHealth's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

MDxHealth Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Valuation Rank
Comparable Companies
FONR ACRS ME VNRX BIOQ ENZ PRE OCX LDDD XGN TMO DHR XSWX:LONN IQV A IDXX MTD ILMN SHSE:603259 WAT
Traded in Other Exchanges
N/A
Address
Zone Industrielle des Hauts-Sarts, Cap Business Center, Herstal, Liege, BEL, 4040
Website
https://www.mdxhealth.com
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.